Kevin Walter Collins insider trades: Lucira Health (LHDX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kevin reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 7, 2023 | LHDX | ↓ Sell | 111,819 | $0.66 | $74K | Direct | Mar 13, 2023 (6d) |
| Nov 27, 2022 | LHDX | ↓ Sell | 9,666 | $0.42 | $4K | Direct | Nov 29, 2022 (2d) |
| Aug 27, 2022 | LHDX | ↓ Sell | 8,580 | $1.72 | $15K | Direct | Aug 29, 2022 (2d) |
| May 27, 2022 | LHDX | ↓ Sell | 37,109 | $2.00 | $74K | Direct | Jul 12, 2022 (46d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Kevin Walter Collins's insider trades
Kevin Walter Collins is Chief Revenue Officer at Lucira Health (LHDX). Since May 27, 2022, Kevin has reported no open-market purchases and 4 sales worth $167K on SEC Form 4. There have been no open-market trades in the last 12 months.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LHDX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.